Difference between revisions of "Malignant melanoma"

Jump to navigation Jump to search

Malignant melanoma (view source)

Revision as of 15:32, 5 November 2021

16,149 bytes added ,  15:32, 5 November 2021
→‎Others
(→‎Subtypes: tweak, add image link)
 
(79 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Image      = Melanoma40x.JPG
| Width      =
| Caption    = Malignant melanoma. [[H&E stain]].
| Micro      = melanocytic differentiation (e.g. pigment), abnormal architecture, lack of maturation, +/-nuclear atypia - esp. nucleoli, +/-upward scatter of melanocytes, +/-asymmetry of pigmentation
| Subtypes  =
| LMDDx      = [[dysplastic nevus]], [[Spitz nevus]], [[common nevus]] (nevoid melanoma), [[atypical fibroxanthoma]], (spindle cell) [[squamous cell carcinoma]], [[leiomyosarcoma]], [[serous carcinoma]], [[clear cell sarcoma]], others
| Stains    = melanin
| IHC        = S-100, Melan A, HMB-45, [[MITF]], tyrosinase
| EM        = melanosomes
| Molecular  = +/-[[BRAF mutation]]
| IF        =
| Gross      =
| Grossing  =
| Site      = [[skin]] (usu. sun exposed areas), oral mucosa, others
| Assdx      =
| Syndromes  = familial melanoma
| Clinicalhx =
| Signs      = ABCDE <nowiki>=</nowiki> asymmetrical, border irregular, colour (black), diameter (>6 mm), evolving (growing)
| Symptoms  =
| Prevalence = common
| Bloodwork  =
| Rads      =
| Endoscopy  =
| Prognosis  = good to very poor (dependent on stage)
| Other      =
| ClinDDx    = pigmented skin lesions, esp. [[melanocytic lesions]]
| Tx        = wide excision if possible
}}
{{ Infobox external links
| Name          = Melanoma in situ
| EHVSC          = 10171
| pathprotocols  =
| wikipedia      =
| pathoutlines  =
}}
'''Malignant melanoma''', also '''melanoma''', is an aggressive type of skin cancer that can be diagnostically challenging for pathologists.   
'''Malignant melanoma''', also '''melanoma''', is an aggressive type of skin cancer that can be diagnostically challenging for pathologists.   


Line 12: Line 49:
*Ulceration.
*Ulceration.
*Regression - >75% of tumour.
*Regression - >75% of tumour.
*Tumour infiltrating lymphocytes.
*Microsatellitosis - nest of tumour cells > 0.05 mm size, separated from primary tumour >=0.3 mm and <= 2 cm.
*Microsatellitosis - nest of tumour cells > 0.05 mm size, separated from primary tumour >=0.3 mm and <= 2 cm.
*In transist metastasis.
*[[In transit metastasis]].
*[[Lymphovascular invasion]].
*[[Lymphovascular invasion]].
*Perineural invasion.
*[[Perineural invasion]].
*Lack of [[tumour infiltrating lymphocytes]] (TILs).{{fact}}


===Clinical===
===Clinical===
*''ABCD'' = asymmetric, borders (irregular), colour (black), diameter (large).
Serologic predictors of a poor prognosis:
Serologic predictors of a poor prognosis:
*Lactate dehydrogenase (LDH) > 200-225 U/L.
*Lactate dehydrogenase (LDH) > 200-225 U/L.
*Alumin < 35 g/L.
*Alumin < 35 g/L.
Epidemiology:
*Strong association with sun exposure.
*Typically Caucasians.
**Blacks rarely get melanoma. When they do it is often on the palms or soles.<ref>{{Ref APBR|362 Q49}}</ref><ref name=pmid17373156>{{Cite journal  | last1 = Byrd-Miles | first1 = K. | last2 = Toombs | first2 = EL. | last3 = Peck | first3 = GL. | title = Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. | journal = J Drugs Dermatol | volume = 6 | issue = 1 | pages = 10-6 | month = Jan | year = 2007 | doi =  | PMID = 17373156 }}</ref>
==Gross==
Memory device ''ABCDE'':<ref name=Ref_Derm466>{{Ref Derm|466}}</ref>
*Asymmetric.
*Borders (irregular).
*Colour (black - variable in lesion).
*Diameter (larger than 6 mm).
*Evolving (change with time).


==Microscopic==
==Microscopic==
===Metatstatic/non-skin===
===Metastatic/non-skin===
Features (non-skin):
Features (non-skin):
*Classic appearance of melanoma:  
*Classic appearance of melanoma:  
Line 46: Line 94:
====DDx====
====DDx====
*Carcinoma.
*Carcinoma.
**Serous carcinoma - both serous carcinoma and melanoma have a large [[nucleolus]].
**[[Serous carcinoma]] - both serous carcinoma and melanoma have a large [[nucleolus]].
*Sarcoma - as may have spindle cells.
*Sarcoma - as may have spindle cells.
**[[Clear cell sarcoma]].
**[[Clear cell sarcoma]] ([[AKA]] melanoma of the soft parts).
**Metaplastic carcinoma.
**[[Metaplastic carcinoma]].
**[[Spindle cell squamous carcinoma]].
**Epithelioid [[angiosarcoma]].
**Epithelioid [[angiosarcoma]].
*Lymphoma.
*Lymphoma.
*Other [[melanocytic lesions]].
*[[Nodal nevus]] - benign nevus in lymph node.
*Other (benign) [[melanocytic lesions]].


Images:
Images:
Line 66: Line 116:
#Architecture:  
#Architecture:  
#*Sheeting - '''diagnostic'''.
#*Sheeting - '''diagnostic'''.
#*Asymmetry - as judged from low power magnification.
#*Asymmetry of architecture - as judged from low power magnification.
#Lack of maturation - see below.
#Lack of maturation - see below.
#+/-[[Nuclear atypia]] - esp. nucleoli.
#+/-[[Nuclear atypia]] - esp. nucleoli.
Line 75: Line 125:
#**Histologic evidence of trauma.
#**Histologic evidence of trauma.
#***Thick dense ''stratum corneum''.  
#***Thick dense ''stratum corneum''.  
#+/-Asymmetry of pigmentation.


Maturation - with depth:
Maturation - with depth:
*Nests get smaller.
*Cells get smaller.
*Cells get smaller.
*Mitoses decrease.
*Mitoses decrease.
*Pigmentation decrease.
*Pigmentation decreases.
*Nests get smaller.
 
Memory device '''CMPA''': '''C'''ells, '''M'''itoses, '''P'''igment, '''A'''ggregates of cells (nests).


DDx:
DDx:
Line 86: Line 139:
**[[Spitz nevus]] - especially difficult.  
**[[Spitz nevus]] - especially difficult.  
***Key differences: maturation and symmetry.
***Key differences: maturation and symmetry.
**[[Melanocytic nevus]].
**[[Melanocytic nevus]] - especially:
***[[Dysplastic nevus]].
*Spindle cell forms:
*Spindle cell forms:
**Spindle cell squamous carcinoma.
**Spindle cell squamous carcinoma.
**[[Atypical fibroxanthoma]].
**[[Atypical fibroxanthoma]].
**[[Leiomyosarcoma]].
**[[Leiomyosarcoma]].
**[[Dermal scar]].
**[[Blue nevus]].


Images:
=====Images=====
======www======
*[http://path.upmc.edu/cases/case429.html Malignant melanoma - several images (upmc.edu)].
*[http://path.upmc.edu/cases/case429.html Malignant melanoma - several images (upmc.edu)].
======MIS======
<gallery>
Image: Malignant melanoma in situ -- very low mag.jpg | MIS - very low mag. (WC/Nephron)
Image: Malignant melanoma in situ -- low mag.jpg | MIS - low mag. (WC/Nephron)
Image: Malignant melanoma in situ -- intermed mag.jpg | MIS - intermed. mag. (WC/Nephron)
Image: Malignant melanoma in situ -- high mag.jpg | MIS - high mag. (WC/Nephron)
Image: Malignant melanoma in situ - alt -- very high mag.jpg | MIS - very high mag. (WC/Nephron)
</gallery>


====Regression of melanoma====
====Regression of melanoma====
Line 102: Line 167:
*Complete regression and partial regression >75% of the lesion are a poor prognostic feature.<ref name=pmid16446717>{{Cite journal  | last1 = Crowson | first1 = AN. | last2 = Magro | first2 = CM. | last3 = Mihm | first3 = MC. | title = Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. | journal = Mod Pathol | volume = 19 Suppl 2 | issue =  | pages = S71-87 | month = Feb | year = 2006 | doi = 10.1038/modpathol.3800517 | PMID = 16446717 }}</ref>
*Complete regression and partial regression >75% of the lesion are a poor prognostic feature.<ref name=pmid16446717>{{Cite journal  | last1 = Crowson | first1 = AN. | last2 = Magro | first2 = CM. | last3 = Mihm | first3 = MC. | title = Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. | journal = Mod Pathol | volume = 19 Suppl 2 | issue =  | pages = S71-87 | month = Feb | year = 2006 | doi = 10.1038/modpathol.3800517 | PMID = 16446717 }}</ref>


Note:
*[[Melanocytic lesions]] in general, ''not'' only melanoma, may regress.<ref name=Ref_Derm476>{{Ref Derm|476}}</ref><ref name=pmid21029398>{{Cite journal  | last1 = Speeckaert | first1 = R. | last2 = van Geel | first2 = N. | last3 = Vermaelen | first3 = KV. | last4 = Lambert | first4 = J. | last5 = Van Gele | first5 = M. | last6 = Speeckaert | first6 = MM. | last7 = Brochez | first7 = L. | title = Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. | journal = Pigment Cell Melanoma Res | volume = 24 | issue = 2 | pages = 334-44 | month = Apr | year = 2011 | doi = 10.1111/j.1755-148X.2010.00799.x | PMID = 21029398 }}</ref>
=====Microscopic=====
=====Microscopic=====
Features - all required:
Features - all required:
Line 122: Line 189:
Note:  
Note:  
*Histology is '''not definitive''' for metastatic melanoma vs. primary melanoma; epidermal involvement may be seen in mets.
*Histology is '''not definitive''' for metastatic melanoma vs. primary melanoma; epidermal involvement may be seen in mets.
**IHC (like histology) is ''not definitive''.<ref name=pmid15272532>{{Cite journal  | last1 = Guerriere-Kovach | first1 = PM. | last2 = Hunt | first2 = EL. | last3 = Patterson | first3 = JW. | last4 = Glembocki | first4 = DJ. | last5 = English | first5 = JC. | last6 = Wick | first6 = MR. | title = Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. | journal = Am J Clin Pathol | volume = 122 | issue = 1 | pages = 70-7 | month = Jul | year = 2004 | doi = 10.1309/FUQH-92B0-3902-5LHG | PMID = 15272532 }}</ref>
**History/clinical is important for differentiation.
**History/clinical is important for differentiation.
====Margin assessment====
{{Main|Surgical margin}}
=====General=====
*Adequate distance dependent on tumour stage - see ''[[Surgical_margins#Adequate_margins_by_tumour|surgical margin]]'' article.
*Margin assessment is notoriously difficult as there are numerous mimics of melanoma in situ:<ref name=pmid21549242>{{Cite journal  | last1 = Trotter | first1 = MJ. | title = Melanoma margin assessment. | journal = Clin Lab Med | volume = 31 | issue = 2 | pages = 289-300 | month = Jun | year = 2011 | doi = 10.1016/j.cll.2011.03.006 | PMID = 21549242 }}</ref>
*#Melanocytic hyperplasia (considered to be on a continuum with melanoma) may be due to:
*#*Light exposure.
*#*Peritumoral-effect.
*#*Previous biopsy.
*#[[Solar lentigo]].
*#Lichenoid reactions.
=====Microscopic=====
Features of [[MIS]]:<ref name=pmid21549242/>
#Pagetoid spread of melanocytes.
#Junctional or intraepidermal melanocytic nests.
#Three of more contiguous melanocytes in the basal layer.
#Increased numbers of basal melanocytes ( > 25 melanocytes / 0.5 mm of basal layer).
#Marked cytologic atypia - multinucleated cells.
#Adenxal involvement.
Lame mnemonic ''MARGIN'':
*'''M'''arked cytologic atypia.
*'''A'''dnexal involvement.
*'''R'''ow of melanocytes.
*'''G'''ravity defying melanocytes (Pagetoid spread).
*'''I'''ncreased basal melanocytes.
*'''N'''ests of melanocytes.
=====Assessment/reporting of margins=====
*There is no general agreement on how to report margins in melanoma.
It is suggested that one should:
#Try to tease apart melanoma cells from benign melanocytes.
#*Use the ''MARGIN'' mnemonic above.
#**Melanocytes with nuclear atypia = melanoma cells.
#Report the clearance of the nearest melanoma cell to the margin.
#*Positive margin = melanoma cell is touching ink.
#*Very close is reported as "clearance < 0.1 mm".
#Use [[immunostain]]s to assist the assessment of difficult cases:
#*MiTF is considered the preferred marker.
#*MART-1 (Melan A) is considered to overestimate melanocytes; it should ''not'' be used.<ref name=pmid21797920>{{Cite journal  | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref>
#*S-100 also marks follicular dendritic cells; it is ''not'' a preferred marker.


====Breslow thickness====
====Breslow thickness====
*[[AKA]] ''maximum tumour thickness''.
*[[AKA]] ''maximum tumour thickness''.
*Depth measured from stratum granulosum to deepest intradermal tumour cell - predictive of survival.<ref name=Ref_PCPBoD8>{{Ref PCPBoD8|595}}</ref>
*Depth measured from [[stratum granulosum]] to deepest intradermal tumour cell - predictive of survival.<ref name=Ref_PCPBoD8>{{Ref PCPBoD8|595}}</ref>


====Clark level====
=====Tumour stage=====
Melanoma staging is based primarily on the Breslow thickness:<ref>{{Cite journal  | last1 = Nowecki | first1 = ZI. | last2 = Rutkowski | first2 = P. | last3 = Michej | first3 = W. | title = The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). | journal = Ann Surg Oncol | volume = 15 | issue = 8 | pages = 2223-34 | month = Aug | year = 2008 | doi = 10.1245/s10434-008-9965-3 | PMID = 18506535 }}</ref><ref>URL: [https://documents.cap.org/protocols/Skin.Melanoma.Bx_4.3.0.1.REL_CAPCP.pdf https://documents.cap.org/protocols/Skin.Melanoma.Bx_4.3.0.1.REL_CAPCP.pdf]. Accessed on: 14 September 2021.</ref>
*pT1 ≤ 1.0 mm.
**pT1a: ≤ 0.8 mm, no ulceration.
**pT1b: ulceration present ''or'' 0.8 mm  < thickness ≤ 1.0 mm (with or without ulceration).
*pT2 1.01 mm to 2.0 mm.
**pT2a: no ulceration.
**pT2b: ulceration present.
*pT3 2.01 mm to 4.0 mm.
**pT3a: no ulceration.
**pT3b: ulceration present.
*pT4 >4.0 mm.
**pT4a: no ulceration.
**pT4b: ulceration present.
 
=====Clark level=====
*[[AKA]] ''anatomic level''.
*[[AKA]] ''anatomic level''.
*Not as reproducible as ''Breslow thickness'' - not used.
*''Not'' as reproducible as ''Breslow thickness''. It is not used for this reason.


Anatomic level - definition:
Anatomic level - definition:
Line 141: Line 268:
====Subtypes====
====Subtypes====
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
| '''Subtype name'''
! Subtype name
| '''Key feature'''
! Key feature
| '''Microscopic additional'''
! Microscopic additional
| '''DDx'''
! DDx
| '''Image'''
! Image
| '''Notes/other'''
! Notes/other
|-
|-
| Melanoma in situ
| Melanoma in situ
| confined to epidermis, nuclear atypia
| confined to epidermis, nuclear atypia
| melanocyte enlargement, nuclear hyperchromasia, +/- melanocytes above suprapapillary plate (above basal layer) = "Pagetoid spread"
| melanocyte enlargement, nuclear hyperchromasia, +/- melanocytes above suprapapillary plate (above basal layer) = "Pagetoid spread"
| melanocytic hyperplasia, pagetoid Spitz nevus
| melanocytic hyperplasia, pagetoid Spitz nevus, [[dysplastic nevus]]<ref name=pmid15953373>{{Cite journal  | last1 = Farrahi | first1 = F. | last2 = Egbert | first2 = BM. | last3 = Swetter | first3 = SM. | title = Histologic similarities between lentigo maligna and dysplastic nevus: importance of clinicopathologic distinction. | journal = J Cutan Pathol | volume = 32 | issue = 6 | pages = 405-12 | month = Jul | year = 2005 | doi = 10.1111/j.0303-6987.2005.00355.x | PMID = 15953373 }}</ref>
| [http://path.upmc.edu/cases/case97/micro.html (upmc.edu)], [http://commons.wikimedia.org/wiki/File:Lentigo_maligna_-_high_mag.jpg (WC)]
| [http://path.upmc.edu/cases/case97/micro.html (upmc.edu)], [http://commons.wikimedia.org/wiki/File:Lentigo_maligna_-_high_mag.jpg (WC)]
| ''lentigo maligna'' (LM) is melanoma in situ<ref name=pmid16681656>{{Cite journal  | last1 = McKenna | first1 = JK. | last2 = Florell | first2 = SR. | last3 = Goldman | first3 = GD. | last4 = Bowen | first4 = GM. | title = Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. | journal = Dermatol Surg | volume = 32 | issue = 4 | pages = 493-504 | month = Apr | year = 2006 | doi = 10.1111/j.1524-4725.2006.32102.x | PMID = 16681656 }}</ref> on sun damaged skin; LM should '''not''' be confused with ''lentigo maligna melanoma'' (LMM)
| ''lentigo maligna'' (LM) is melanoma in situ<ref name=pmid16681656>{{Cite journal  | last1 = McKenna | first1 = JK. | last2 = Florell | first2 = SR. | last3 = Goldman | first3 = GD. | last4 = Bowen | first4 = GM. | title = Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. | journal = Dermatol Surg | volume = 32 | issue = 4 | pages = 493-504 | month = Apr | year = 2006 | doi = 10.1111/j.1524-4725.2006.32102.x | PMID = 16681656 }}</ref> on sun damaged skin; LM should '''not''' be confused with ''lentigo maligna melanoma'' (LMM)
Line 177: Line 304:
|-
|-
| Malignant melanoma - desmoplastic-neurotropic type [[AKA]] desmoplastic melanoma
| Malignant melanoma - desmoplastic-neurotropic type [[AKA]] desmoplastic melanoma
| large atypical spindle cells, btw collagen
| large atypical spindle cells, between collagen
| predominantly dermal
| predominantly dermal, +/-lymphocytes (nodules or infiltrating)<ref>URL: [http://path.upmc.edu/cases/case378/dx.html http://path.upmc.edu/cases/case378/dx.html]. Accessed on: 1 June 2012.</ref>
| [[pleomorphic undifferentiated sarcoma]] (MFH), [[scar]], [[dermatofibroma]], [[DFSP]], [[leiomyosarcoma]], desmoplastic [[Spitz nevus]], sclerosing [[blue nevus]]
| [[pleomorphic undifferentiated sarcoma]] (MFH), [[scar]], [[dermatofibroma]], [[DFSP]], [[leiomyosarcoma]], desmoplastic [[Spitz nevus]], sclerosing [[blue nevus]]
| [http://path.upmc.edu/cases/case378.html (upmc.edu)]
| [http://path.upmc.edu/cases/case378.html (upmc.edu)]
Line 200: Line 327:
====Subtypes in short====
====Subtypes in short====
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
| '''Subtype name'''
! Subtype name
| '''Key feature'''
! Key feature
|-
|-
| in situ
| in situ
Line 226: Line 353:


==[[Electron microscopy]]==
==[[Electron microscopy]]==
*Melanosomes.
*[[Melanosomes]].


Image(s):
Image(s):
Line 232: Line 359:


==Stains==
==Stains==
*''Fontana-Masson stain'', stains melanin.<ref>URL: [http://education.vetmed.vt.edu/curriculum/VM8054/labs/Lab2/Examples/exfontana.htm http://education.vetmed.vt.edu/curriculum/VM8054/labs/Lab2/Examples/exfontana.htm]. Accessed on: 5 May 2010.</ref>
*''[[Fontana-Masson stain]]'', stains melanin.<ref>URL: [http://education.vetmed.vt.edu/curriculum/VM8054/labs/Lab2/Examples/exfontana.htm http://education.vetmed.vt.edu/curriculum/VM8054/labs/Lab2/Examples/exfontana.htm]. Accessed on: 5 May 2010.</ref>
**May be useful to differentiate melanin from other brown stuff (e.g. lipofuscin, hemosiderin).
**May be useful to differentiate melanin from other brown stuff (e.g. lipofuscin, hemosiderin).


==[[IHC]]==
==[[IHC]]==
Standard panel:
===Standard panel===
#S100 +ve.
#S-100 +ve.
#*Negative staining pretty much excludes the diagnosis.
#*Negative staining pretty much excludes the diagnosis.
#HMB-45 +ve -- esp. deep.
#HMB-45 +ve -- especially deep, often patchy.
#Melan A (MART-1) +ve.
#Melan A (MART-1) +ve.


Others:
Notes:
*SOX10 +ve -- useful for diff. from excision scar.<ref name=pmid20653825>{{cite journal |author=Ramos-Herberth FI, Karamchandani J, Kim J, Dadras SS |title=SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar |journal=J. Cutan. Pathol. |volume=37 |issue=9 |pages=944–52 |year=2010 |month=September |pmid=20653825 |doi=10.1111/j.1600-0560.2010.01568.x |url=}}</ref>
*The standard panel above (S100, HMB-45, MART-1) is also positive in other lesions, e.g. ''[[cellular blue nevus]]''.
**SOX-10 = pan-schwannian and melanocytic marker.
*Melan A tends to overestimate the number of melanocytes.<ref name=pmid21797920>{{Cite journal | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref>
**Counting the cell bodies may give an accurate result.{{fact}}
*S-100 marks melanocytes and follicular dendritic cells.
 
===Threshold panel===
When one it sure it is melanocytic... but unsure whether it is melanoma:
*HMB-45 +ve deep melanocytes.
**In benign lesions deep (mature) melanocytes are negative.
*Ki-67.
 
===Sentinel lymph node panel===
{{Main|Sentinel lymph node}}
Three sets of the following (12 slides in total):
*[[H&E stain|H&E]].
*S-100.
*MART-1.
*HMB-45.


Notes:
Notes:
*The standard panel above (S100, HMB-45, MART-1) is also positive in other lesions, e.g. ''[[cellular blue nevus]]''.
*Positive in approximately 20% of cases - based on one series.<ref name=pmid24455276>{{cite journal |author=Teixeira V, Vieira R, Coutinho I, ''et al.'' |title=Prediction of sentinel node status and clinical outcome in a melanoma centre |journal=J Skin Cancer |volume=2013 |issue= |pages=904701 |year=2013 |pmid=24455276 |pmc=3886376 |doi=10.1155/2013/904701 |url=}}</ref>
**Strongly dependent on T-stage (T1 ~5%, T2 ~11%, T3 ~28%, T4 ~47%).
 
===Others===
*[[SOX10]] +ve -- useful for differentiate from excision scar.<ref name=pmid20653825>{{cite journal |author=Ramos-Herberth FI, Karamchandani J, Kim J, Dadras SS |title=SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar |journal=J. Cutan. Pathol. |volume=37 |issue=9 |pages=944–52 |year=2010 |month=September |pmid=20653825 |doi=10.1111/j.1600-0560.2010.01568.x |url=}}</ref>
**SOX10 = pan-schwannian and melanocytic marker.
*[[CD99]] +ve.
 
*Melanoma cocktail (HMB-45, MART-1).<ref name=pmid18360125>{{cite journal |author=Jani P, Chetty R, Ghazarian DM |title=An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature |journal=Am J Dermatopathol |volume=30 |issue=2 |pages=174–7 |year=2008 |month=April |pmid=18360125 |doi=10.1097/DAD.0b013e318165b8fe |url=}}</ref>
*[[Microphthalmia transcription factor]] (MITF) - easy to interpret as it is a nuclear stain.<ref>{{OMIM|156845}}</ref><ref name=pmid16899407>{{Cite journal  | last1 = Levy | first1 = C. | last2 = Khaled | first2 = M. | last3 = Fisher | first3 = DE. | title = MITF: master regulator of melanocyte development and melanoma oncogene. | journal = Trends Mol Med | volume = 12 | issue = 9 | pages = 406-14 | month = Sep | year = 2006 | doi = 10.1016/j.molmed.2006.07.008 | PMID = 16899407 }}</ref>
*Tyrosinase.<ref name=pmid17227112>{{Cite journal  | last1 = Roma | first1 = AA. | last2 = Magi-Galluzzi | first2 = C. | last3 = Zhou | first3 = M. | title = Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas. | journal = Arch Pathol Lab Med | volume = 131 | issue = 1 | pages = 122-5 | month = Jan | year = 2007 | doi = 10.1043/1543-2165(2007)131[122:DEOMMI]2.0.CO;2 | PMID = 17227112 }}</ref>
*WT1 usually +ve<ref name=pmid17927581>{{cite journal |author=Wilsher M, Cheerala B |title=WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections |journal=Histopathology |volume=51 |issue=5 |pages=605–10 |year=2007 |month=November |pmid=17927581 |doi=10.1111/j.1365-2559.2007.02843.x |url=}}</ref> - not commonly used.
 
==Molecular==
* Commonly have [[BRAF mutation]]s.<ref name=pmid12460918>{{Cite journal  | last1 = Brose | first1 = MS. | last2 = Volpe | first2 = P. | last3 = Feldman | first3 = M. | last4 = Kumar | first4 = M. | last5 = Rishi | first5 = I. | last6 = Gerrero | first6 = R. | last7 = Einhorn | first7 = E. | last8 = Herlyn | first8 = M. | last9 = Minna | first9 = J. | title = BRAF and RAS mutations in human lung cancer and melanoma. | journal = Cancer Res | volume = 62 | issue = 23 | pages = 6997-7000 | month = Dec | year = 2002 | doi =  | PMID = 12460918 }}
</ref>
* Desmoplastic melanoma has the highest number of mutations (62 per megabase).<ref>{{Cite journal  | last1 = Shain | first1 = AH. | last2 = Garrido | first2 = M. | last3 = Botton | first3 = T. | last4 = Talevich | first4 = E. | last5 = Yeh | first5 = I. | last6 = Sanborn | first6 = JZ. | last7 = Chung | first7 = J. | last8 = Wang | first8 = NJ. | last9 = Kakavand | first9 = H. | title = Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. | journal = Nat Genet | volume = 47 | issue = 10 | pages = 1194-9 | month = Oct | year = 2015 | doi = 10.1038/ng.3382 | PMID = 26343386 }}</ref>
**The high number of (C>T) transitions suggest UV radiation as main cause.
**Approx. 15% of the cases have NFKBIE amplifications.
 
==Sign out==
===Melanoma in situ===
<pre>
Skin Lesion, Left Upper Back, Re-excision:
- Melanoma in situ, completely excised.
-- Surgical clearance 8 millimetres.
- Dermal scar.
- Solar elastosis.
 
Comment:
The case was partially reviewed with Dr. X; he agrees melanoma in situ is present.
</pre>
 
====Block letters====
<pre>
SKIN LESION, MID-MIDDLE BACK, PUNCH BIOPSY:
- MELANOMA IN SITU, NEAREST (LATERAL) MARGIN APPROXIMATELY 1 MM -- WIDE RE-EXCISION SHOULD BE DONE.
 
COMMENT:
The lesion is characterized by mild nuclear atypia and marked architectural complexity. 
It has lamellar fibrosis and multiple foci of complex rete ridge bridging and pagetoid
spread of melanocytes. Mitotic activity is seen focally.
</pre>
 
<pre>
SKIN LESION, MID BACK, EXCISION:
- LENTIGO MALIGNA (SOLAR ELASTOSIS AND MELANOMA IN SITU), MARGIN CLEARANCE < 0.1 MM.
 
COMMENT:
This lesion should be re-excised.
</pre>
 
<pre>
SKIN LESION, MID BACK, EXCISION:
- MELANOMA IN SITU AND SOLAR ELASTOSIS (LENTIGO MALIGNA), MARGIN CLEARANCE 2 MM.
 
COMMENT:
The presence of melanoma in situ is confirmed with immunostaining (HMB-45, MITF).
 
This lesion should be re-excised.
</pre>
 
====At least MIS====
<pre>
LEFT THUMB NAIL, AVULSION AND NAIL MATRIX BIOPSY:
- AT LEAST MALIGNANT MELANOMA IN SITU.
 
COMMENT:
The quantity of diagnostic material is suboptimal.
 
The limited number of lesional cells stain as follows:
POSITIVE: S-100, HMB-45, MITF, Melan A.
 
An internal review confirms the impression of at least melanoma in situ.
</pre>
 
====Micro====
The sections show hair-bearing skin with atypical melanocytes confined to the epidermis.
The melanocytes scatter upwards (focally), have confluent growth and nucleoli, and involve
the adnexal structures. Occasional large multi-nucleated melanocytes, with their nuclei
arranged around the cell periphery, are present. Mitotic activity is not apparent. Extensive solar elastosis is present.
 
The lesion is very close to the margin (<0.1 mm clearance).
 
=====Alternate=====
The sections show skin with pigmented atypical melanocytes confined to the epidermis. The melanocytes scatter upwards, and have focal confluent growth and nucleoli.  Mitotic activity is not apparent. Solar elastosis is present in the background. The lesion extends to the edge of the tissue; it is incompletely excised.
 
===Invasive melanoma===
<pre>
SKIN LESION, LEFT LOWER BACK, SHAVE BIOPSY:
- INVASIVE MALIGNANT MELANOMA.
-- AT LEAST pT3a.
-- 6 MITOSES/MM*MM.
-- DEEP AND LATERAL MARGINS POSITIVE, WIDE RE-EXCISION SHOULD BE DONE.
-- PLEASE SEE TUMOUR SUMMARY.
-- PLEASE SEE COMMENT.
 
COMMENT:
The morphologic impression is confirmed by immunostains; the tumour is POSITIVE for
S-100, HMB-45, and MART-1.
</pre>


==See also==
==See also==
Line 257: Line 500:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
==External links==
*[https://www.youtube.com/watch?v=_4jgUcxMezM Dear 16-year-old me - DCMFCanada (youtube.com)].


[[Category:Dermatopathology]]
[[Category:Dermatopathology]]
[[Category:Diagnosis]]
[[Category:Diagnosis]]
Michael
48,830

edits

Retrieved from "https://librepathology.org/wiki/Special:MobileDiff/16457...51617"

Navigation menu